Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-in-human study of JNJ-67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome.
Narayan R, Piérola AA, Donnellan WB, Yordi AM, Abdul-Hay M, Platzbecker U, Subklewe M, Kadia TM, Alonso-Domínguez JM, McCloskey J, Bradford K, Curtis M, Daskalakis N, Guttke C, Safer K, Hiebert B, Murphy J, Li X, Duchin K, Esteban D. Narayan R, et al. Among authors: donnellan wb. Clin Transl Sci. 2024 Mar;17(3):e13742. doi: 10.1111/cts.13742. Clin Transl Sci. 2024. PMID: 38494922 Free PMC article. Clinical Trial.
A 2:1 randomized, open-label, phase II study of selinexor vs. physician's choice in older patients with relapsed or refractory acute myeloid leukemia.
Sweet K, Bhatnagar B, Döhner H, Donnellan W, Frankfurt O, Heuser M, Kota V, Liu H, Raffoux E, Roboz GJ, Röllig C, Showel MM, Strickland SA Jr, Vives S, Tang S, Unger TJ, Joshi A, Shen Y, Alvarez MJ, Califano A, Crochiere M, Landesman Y, Kauffman M, Shah J, Shacham S, Savona MR, Montesinos P. Sweet K, et al. Leuk Lymphoma. 2021 Dec;62(13):3192-3203. doi: 10.1080/10428194.2021.1950706. Epub 2021 Jul 29. Leuk Lymphoma. 2021. PMID: 34323164 Clinical Trial.
Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.
Watts JM, Baer MR, Yang J, Prebet T, Lee S, Schiller GJ, Dinner SN, Pigneux A, Montesinos P, Wang ES, Seiter KP, Wei AH, De Botton S, Arnan M, Donnellan W, Schwarer AP, Récher C, Jonas BA, Ferrell PB Jr, Marzac C, Kelly P, Sweeney J, Forsyth S, Guichard SM, Brevard J, Henrick P, Mohamed H, Cortes JE. Watts JM, et al. Lancet Haematol. 2023 Jan;10(1):e46-e58. doi: 10.1016/S2352-3026(22)00292-7. Epub 2022 Nov 10. Lancet Haematol. 2023. PMID: 36370742 Clinical Trial.
First-in-human study of JNJ-63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemia.
Boyiadzis M, Desai P, Daskalakis N, Donnellan W, Ferrante L, Goldberg JD, Grunwald MR, Guttke C, Li X, Perez-Simon JA, Salamero O, Tucker T, Xu X, Yang J, Pemmaraju N, Alonso-Dominguez JM. Boyiadzis M, et al. Clin Transl Sci. 2023 Mar;16(3):429-435. doi: 10.1111/cts.13467. Epub 2023 Jan 16. Clin Transl Sci. 2023. PMID: 36564917 Free PMC article.
Lenalidomide and Eltrombopag for Treatment of Low- or Intermediate-Risk Myelodysplastic Syndrome: Result of a Phase II Clinical Trial.
Gonzalez-Lugo JD, Kambhampati S, Yacoub A, Donnellan WB, Berdeja J, Bhagat P, Fehn K, Remy C, Jasra S, Kazemi M, Pradhan K, Kim M, Mantzaris I, Sica RA, Shah N, Goldfinger M, Kornblum N, Gritsman K, Braunschweig I, Steidl U, Will B, Shastri A, Verma A. Gonzalez-Lugo JD, et al. Among authors: donnellan wb. Clin Cancer Res. 2023 Jan 4;29(1):60-66. doi: 10.1158/1078-0432.CCR-22-1457. Clin Cancer Res. 2023. PMID: 36255372 Clinical Trial.
Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies.
Patel MR, Donnellan W, Byrne M, Asch AS, Zeidan AM, Baer MR, Fathi AT, Kuykendall AT, Zheng F, Walker C, Cheng L, Marando C, Savona MR. Patel MR, et al. Clin Lymphoma Myeloma Leuk. 2023 Sep;23(9):674-686. doi: 10.1016/j.clml.2023.05.002. Epub 2023 May 15. Clin Lymphoma Myeloma Leuk. 2023. PMID: 37290996 Clinical Trial.
A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.
Manda S, Anz BM 3rd, Benton C, Broun ER, Yimer HA, Renshaw JS, Geils G Jr, Berdeja J, Cruz J, Melear JM, Fanning S, Fletcher L, Li Y, Duan Y, Werner ME, Potluri J, Pai MV, Donnellan WB. Manda S, et al. Among authors: donnellan wb. Hematol Oncol. 2024 May;42(3):e3274. doi: 10.1002/hon.3274. Hematol Oncol. 2024. PMID: 38711253 Clinical Trial.
18 results